Editorial & Columns Valuation Premium: India-listed Subsidiaries of Pharma and Healthcare MNCs Outshine Parent firms June 26, 2024 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Foreign Direct Investment and Pharmaceutical Industry in India April 5, 2024 | Dr. Anil Kumar Angrish | No Comments | More
